Investing.com – Merck&Co reported on Thursday fourth quarter that missed analysts’ forecasts and revenue that fell short of expectations.
Merck&Co announced earnings per share of $1.32 on revenue of $12.51B. Analysts polled by Investing.com anticipated EPS of $1.38 on revenue of $12.67B.
Merck&Co shares are down 5% from the beginning of the year, still down 13.32% from its 52 week high of $89.20 set on February 4, 2020. They are under-performing the Dow Jones which is up 0.38% from the start of the year.
Merck&Co follows other major Healthcare sector earnings this month
Merck&Co’s report follows an earnings beat by J&J on January 26, who reported EPS of $1.86 on revenue of $22.48B, compared to forecasts EPS of $1.82 on revenue of $21.66B.
Abbott Labs had beat expectations on January 27 with fourth quarter EPS of $1.45 on revenue of $10.7B, compared to forecast for EPS of $1.35 on revenue of $9.94B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.